Andelyn Biosciences, Feb. 21 -- Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has expanded its AAV CuratorTM Platform offering and License Agreement with the Broad Institute of MIT and Harvard to include the Stanton Lab CNS (Central Nervous System) capsids. Developed by researchers at the Broad Institute, these plasmids produce adeno-associated viruses (AAVs) that increase brain transduction and reduce tropism for the liver and other peripheral organs.

The expanded agreement is an extension of Andelyn's MyoAAV plasmids License Agreement with Broad Institute announced in August 2024. The Agreement allows Andelyn to use the Stanton Lab CNS capsids to perform research a...